Fibrosis Clinical Trial
Official title:
Does Fibrosis Diathesis Influence the Recovery of Knee Mobility After Total Knee Replacement?
At the standard follow-up moment one year after primary TKA for gonarthrosis, all patients
will be checked for signs of fibrosis diathesis. This will be done by examining their hands
for Dupuytren's nodules and contractures and recording risk factors associated with
increased severity and risk of recurrence of Dupuytren's contracture. These include family
history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender,
Ledderhose disease, first ray involvement, multiple ray involvement and ectopic
fibromatosis.
This way, two groups of patients will be identified: those with and those without signs of
fibrosis diathesis. For both groups, the range of motion (ROM) of the operated knee at 3 and
6 months will be retrieved in the charts, the ROM at 12 months will be measured at that
time. Also, additional procedures performed to increase ROM postoperatively will be
retrieved from the charts (e.g. continuous passive motion, mobilization under anesthesia).
Other causes for knee stiffness will have to be recorded, since these will be the most
important exclusion criteria.
In the patients with clear signs of finger contractures, any impression of increase of
contracture over the past 12 months will be recorded.
n/a
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05570058 -
Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Completed |
NCT03979417 -
Identification of Biomarkers Related to Liver Fibrosis as New Therapeutic Targets
|
||
| Completed |
NCT02408744 -
Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00148837 -
Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis
|
Phase 2 | |
| Recruiting |
NCT05661123 -
Effect of Modified Complete Decongestive Therapy on Lower Limbs Fibrosis Post Cellulitis
|
N/A | |
| Recruiting |
NCT04795570 -
Urethral Stricture After Transurethral Resection of the Prostate/Bladder: a Prospective Study of Risk Factors
|
||
| Active, not recruiting |
NCT05075785 -
Covid-19 Respiratory Sequelae French Cohort
|
||
| Recruiting |
NCT03308916 -
Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
|
N/A | |
| Recruiting |
NCT05459259 -
Physiotherapy for Arthrofibrosis Following Knee Replacement.
|
||
| Enrolling by invitation |
NCT01483248 -
Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
|
Phase 1/Phase 2 | |
| Completed |
NCT00001729 -
Combination Drug Therapy for Patients With Hepatitis C
|
Phase 3 | |
| Completed |
NCT02049307 -
Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial
|
Phase 2 | |
| Active, not recruiting |
NCT05685823 -
The Impact of Conventional Hemodialysis and Renal Transplantation on the Global Longitudinal Strain of the Left Ventricle
|
||
| Completed |
NCT00744939 -
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
|
Phase 4 | |
| Completed |
NCT00252642 -
Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C
|
N/A | |
| Recruiting |
NCT04934202 -
Cohort Follow-up of Survivors of Hospitalization for COVID-19 During the 2nd Wave of the Epidemic in France
|
||
| Completed |
NCT02604862 -
Imaging FIB ONE in the Human Lung Using Endomicroscopy
|
Early Phase 1 | |
| Completed |
NCT02774161 -
B-mode Ultrasound Imaging in Detecting Early Liver Cancer
|
N/A | |
| Active, not recruiting |
NCT01246388 -
Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy
|
N/A | |
| Completed |
NCT02161952 -
Pirfenidone, an Antifibrotic and Antiinflammatory Drug
|
Phase 2 |